Published in J Neurochem on August 01, 2001
Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 3.81
Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem (2008) 2.86
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol (2004) 2.51
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol (2003) 1.75
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol (2003) 1.67
Role of proteasomes in disease. BMC Biochem (2007) 1.65
Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol (2012) 1.59
Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A (2009) 1.56
Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol (2002) 1.43
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40
Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell (2003) 1.23
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics (2006) 1.16
Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol (2007) 1.08
Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc Natl Acad Sci U S A (2013) 1.07
Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.07
Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol (2012) 1.07
Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem (2010) 1.07
Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation. J Cell Mol Med (2008) 0.92
Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front Aging Neurosci (2010) 0.88
The ubiquitin-proteasome system in spongiform degenerative disorders. Biochim Biophys Acta (2008) 0.86
Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact Funct Neurosurg (2009) 0.85
Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition. PLoS One (2010) 0.85
Quantitative analysis of α-synuclein solubility in living cells using split GFP complementation. PLoS One (2012) 0.85
Genetic and chemical activation of TFEB mediates clearance of aggregated α-synuclein. PLoS One (2015) 0.84
The emerging role of proteolysis in mitochondrial quality control and the etiology of Parkinson's disease. Parkinsons Dis (2012) 0.84
BPOZ-2 Gene Delivery Ameliorates Alpha-Synucleinopathy in A53T Transgenic Mouse Model of Parkinson's Disease. Sci Rep (2016) 0.82
Legal but lethal: functional protein aggregation at the verge of toxicity. Front Cell Neurosci (2015) 0.81
Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential. Cell Biochem Biophys (2013) 0.81
Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice. Neurobiol Dis (2013) 0.81
Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. J Neurochem (2008) 0.81
Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm (Vienna) (2008) 0.79
Proteasome inhibition modulates kinase activation in neural cells: relevance to ubiquitination, ribosomes, and survival. J Neurosci Res (2009) 0.78
Pros and cons of a prion-like pathogenesis in Parkinson's disease. BMC Neurol (2011) 0.78
Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. J Neural Transm (Vienna) (2012) 0.78
Activation of PERK kinase in neural cells by proteasome inhibitor treatment. J Neurochem (2009) 0.78
Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein. Acta Pharmacol Sin (2013) 0.77
The Proteasome Inhibition Model of Parkinson's disease. J Parkinsons Dis (2016) 0.76
Heat shock protein defenses in the neocortex and allocortex of the telencephalon. Neurobiol Aging (2015) 0.76
Astrocytes Surviving Severe Stress Can Still Protect Neighboring Neurons from Proteotoxic Injury. Mol Neurobiol (2015) 0.76
Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dual-hit hypothesis of neurodegeneration. Hippocampus (2016) 0.75
Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease. Neurotox Res (2014) 0.75
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 6.92
Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci (2001) 3.10
Presynaptic recording of quanta from midbrain dopamine neurons and modulation of the quantal size. J Neurosci (1998) 2.02
EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med (1992) 1.97
Autophagy in neurons: a review. Histol Histopathol (2002) 1.96
Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron (1997) 1.83
Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci (2000) 1.81
Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A (2000) 1.81
Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci (1994) 1.68
Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci (2001) 1.68
Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J Neurosci (1992) 1.62
Voltammetric and pharmacological characterization of dopamine release from single exocytotic events at rat pheochromocytoma (PC12) cells. Anal Chem (1998) 1.47
Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurol (2013) 1.43
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum Mol Genet (2001) 1.42
Quantitative and statistical analysis of the shape of amperometric spikes recorded from two populations of cells. J Neurochem (2000) 1.39
Multicenter external validation of the ABCD2 score in triaging TIA patients. Neurology (2010) 1.25
Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci (1998) 1.21
D2-Like dopamine autoreceptor activation reduces quantal size in PC12 cells. J Neurosci (1998) 1.20
L-3,4-dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J Neurochem (1996) 1.17
The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci U S A (1996) 1.16
Nedd2 is required for apoptosis after trophic factor withdrawal, but not superoxide dismutase (SOD1) downregulation, in sympathetic neurons and PC12 cells. J Neurosci (1997) 1.10
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
The neuromelanin of human substantia nigra and its interaction with metals. J Neural Transm (Vienna) (2002) 1.00
Involvement of caspase 3 in apoptotic death of cortical neurons evoked by DNA damage. Mol Cell Neurosci (2000) 0.99
Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem (1997) 0.99
Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem (1998) 0.99
Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem (1999) 0.99
Delaying caspase activation by Bcl-2: A clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2000) 0.98
Increased superoxide dismutase activity improves survival of cultured postnatal midbrain neurons. J Neurochem (1996) 0.98
[EDTA versus placebo treatment in intermittent claudication. A double-blind, randomized trial]. Ugeskr Laeger (1992) 0.95
Cyclin-dependent kinases and P53 pathways are activated independently and mediate Bax activation in neurons after DNA damage. J Neurosci (2001) 0.94
Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis (1998) 0.94
Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem (1997) 0.92
Plasticity of quantal size in ventral midbrain dopamine neurons: possible implications for the neurochemistry of feeding and reward. Appetite (1998) 0.91
Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra. J Neurochem (1999) 0.90
Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur J Neurosci (2001) 0.90
Pediatric renal transplantation without steroids. Pediatr Nephrol (1998) 0.88
Ubiquitinated inclusions and neuronal cell death. Histol Histopathol (2003) 0.87
Rare Late-Onset Presentation of Glutaric Aciduria Type I in a 16-Year-Old Woman with a Novel GCDH Mutation. JIMD Rep (2014) 0.86
Apoptosis and the conformational change of Bax induced by proteasomal inhibition of PC12 cells are inhibited by bcl-xL and bcl-2. Apoptosis (2005) 0.85
Activity and activation of the complement system in patients being operated on for cancer of the colon. Eur J Surg (1994) 0.85
Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol Histopathol (2001) 0.84
Lymphangioleiomyomatosis. Is fine needle aspiration cytodiagnosis possible? Acta Cytol (1988) 0.83
alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat Med (2001) 0.83
Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res Bull (2001) 0.83
RAIDD is required for apoptosis of PC12 cells and sympathetic neurons induced by trophic factor withdrawal. Cell Death Differ (2006) 0.83
Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells. Br J Pharmacol (2014) 0.82
RAIDD aggregation facilitates apoptotic death of PC12 cells and sympathetic neurons. Cell Death Differ (2004) 0.81
The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J Neural Transm Suppl (2003) 0.80
Inhibitors of trypsin-like serine proteases prevent DNA damage-induced neuronal death by acting upstream of the mitochondrial checkpoint and of p53 induction. Neuroscience (2001) 0.80
Endovascular repair of postoperative vascular graft related complications after aorto-iliac surgery. Int Angiol (2014) 0.79
A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol Pharmacol (1998) 0.79
Mechanisms of neuronal degeneration: a final common pathway? Adv Neurol (1997) 0.79
[Insulin induced edema]. Ugeskr Laeger (1982) 0.79
Modulation of quantal dopamine release by psychostimulants. Adv Pharmacol (1998) 0.79
Visualization of antipsychotic drug binding to living mesolimbic neurons reveals D2 receptor, acidotropic, and lipophilic components. J Neurochem (1995) 0.78
Electrochemical detection of reverse transport from Planorbis giant dopamine neuron. Methods Enzymol (1998) 0.77
Bacteriological autopsy. I. A methodological study. APMIS (1991) 0.77
Cardiac pathology after isolated valve replacement for aortic stenosis in relation to preoperative patient status. Early and late autopsy findings. Scand J Thorac Cardiovasc Surg (1989) 0.77
Ordering the multiple pathways of apoptosis. Trends Cardiovasc Med (1997) 0.76
Alcian blue and neutral red staining of retinal synaptic layers. J Histochem Cytochem (1986) 0.76
[Lymphangioleiomyomatosis as the cause of chylothorax]. Ugeskr Laeger (1988) 0.75
[Aortic aneurysm with fistula into the colon]. Ugeskr Laeger (1978) 0.75
Laparoscopic sterilization with the Falope-ring. Peroperative and late complications, method safety and a randomized investigation of immediate postoperative abdominal pain. Acta Obstet Gynecol Scand (1983) 0.75
Calmodulin inhibitors block quantal catecholamine release and increase acidification of neurosecretory granules in rat adrenal chromaffin cells. Ann N Y Acad Sci (2002) 0.75
Percutaneous transluminal treatment of an iliac pseudoaneurysm with endoprosthesis implantation. A case report. Acta Radiol (1996) 0.75
Experiments on the use of DAMP to study retina and cultured neurons. J Histochem Cytochem (1990) 0.75
MAVEN at the Mayo Clinic. Med Ref Serv Q (1999) 0.75
[Changes in sexual function after hysterectomy]. Ugeskr Laeger (1982) 0.75
Bilateral cystic seminal vesicles associated with unilateral renal agenesis. Eur Urol (1983) 0.75
Organ donation: number of brain deaths, refusal rate, actual donation, and multiorgan transplantation 1990-1994 in a Danish population of 1 million compared to the whole of Denmark. Transplant Proc (1995) 0.75
Inoperable oesophageal and cardia cancer. Benefits from Celestin intubation. Scand J Thorac Cardiovasc Surg (1987) 0.75
Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients. Transplant Proc (1995) 0.75
S-100 protein in malignant mesotheliomas. Acta Pathol Microbiol Immunol Scand A (1985) 0.75
[Stomach perforation at laparoscopy]. Ugeskr Laeger (1981) 0.75
[Skin changes in the breast]. Ugeskr Laeger (1987) 0.75
[Surgically treated abdominal lymphangioma simulating appendicitis]. Ugeskr Laeger (1983) 0.75
Insulin independence after allogeneic intraportal islet transplantation: relation to functional tests. Transplant Proc (1998) 0.75
Angiomyolipoma causing spontaneous rupture of the kidney. Urol Int (1983) 0.75
Islet and kidney transplantation using ATG and cyclosporin monotherapy and a central facility for islet isolation and purification. Transplant Proc (1995) 0.75